GeoVax Labs (GOVX) Competitors $0.48 +0.00 (+0.69%) As of 01:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GOVX vs. PMVP, SNTI, CRVO, CNTB, ANL, AVTX, GANX, KRON, OTLK, and INMBShould you be buying GeoVax Labs stock or one of its competitors? The main competitors of GeoVax Labs include PMV Pharmaceuticals (PMVP), Senti Biosciences (SNTI), CervoMed (CRVO), Connect Biopharma (CNTB), Adlai Nortye (ANL), Avalo Therapeutics (AVTX), Gain Therapeutics (GANX), Kronos Bio (KRON), Oncobiologics (OTLK), and INmune Bio (INMB). These companies are all part of the "pharmaceutical products" industry. GeoVax Labs vs. Its Competitors PMV Pharmaceuticals Senti Biosciences CervoMed Connect Biopharma Adlai Nortye Avalo Therapeutics Gain Therapeutics Kronos Bio Oncobiologics INmune Bio GeoVax Labs (NASDAQ:GOVX) and PMV Pharmaceuticals (NASDAQ:PMVP) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment and earnings. Which has better earnings & valuation, GOVX or PMVP? GeoVax Labs has higher revenue and earnings than PMV Pharmaceuticals. PMV Pharmaceuticals is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGeoVax Labs$3.95M1.94-$24.99M-$3.65-0.13PMV PharmaceuticalsN/AN/A-$58.71M-$1.18-1.03 Does the media prefer GOVX or PMVP? In the previous week, PMV Pharmaceuticals had 1 more articles in the media than GeoVax Labs. MarketBeat recorded 7 mentions for PMV Pharmaceuticals and 6 mentions for GeoVax Labs. PMV Pharmaceuticals' average media sentiment score of 0.00 beat GeoVax Labs' score of -0.39 indicating that PMV Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GeoVax Labs 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral PMV Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is GOVX or PMVP more profitable? PMV Pharmaceuticals has a net margin of 0.00% compared to GeoVax Labs' net margin of -438.20%. PMV Pharmaceuticals' return on equity of -32.54% beat GeoVax Labs' return on equity.Company Net Margins Return on Equity Return on Assets GeoVax Labs-438.20% -511.96% -286.58% PMV Pharmaceuticals N/A -32.54%-29.59% Which has more volatility & risk, GOVX or PMVP? GeoVax Labs has a beta of 3.36, meaning that its share price is 236% more volatile than the S&P 500. Comparatively, PMV Pharmaceuticals has a beta of 1.49, meaning that its share price is 49% more volatile than the S&P 500. Do analysts rate GOVX or PMVP? GeoVax Labs currently has a consensus price target of $11.10, suggesting a potential upside of 2,212.02%. PMV Pharmaceuticals has a consensus price target of $5.50, suggesting a potential upside of 354.55%. Given GeoVax Labs' stronger consensus rating and higher probable upside, equities research analysts plainly believe GeoVax Labs is more favorable than PMV Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GeoVax Labs 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29PMV Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals have more ownership in GOVX or PMVP? 6.1% of GeoVax Labs shares are held by institutional investors. Comparatively, 90.2% of PMV Pharmaceuticals shares are held by institutional investors. 1.2% of GeoVax Labs shares are held by insiders. Comparatively, 7.6% of PMV Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. SummaryGeoVax Labs and PMV Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks. Get GeoVax Labs News Delivered to You Automatically Sign up to receive the latest news and ratings for GOVX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GOVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GOVX vs. The Competition Export to ExcelMetricGeoVax LabsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.59M$2.91B$5.54B$8.95BDividend YieldN/A2.42%5.38%4.08%P/E Ratio-0.1321.5627.4020.04Price / Sales1.94281.10419.46118.60Price / CashN/A41.9536.6357.47Price / Book1.007.518.085.67Net Income-$24.99M-$55.05M$3.16B$248.47M7 Day Performance-49.46%3.16%2.12%2.90%1 Month Performance-54.28%5.92%4.43%5.75%1 Year Performance-83.44%5.82%35.62%21.36% GeoVax Labs Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GOVXGeoVax Labs3.3641 of 5 stars$0.48+0.7%$11.10+2,212.0%-85.6%$7.59M$3.95M-0.1310News CoveragePMVPPMV Pharmaceuticals2.5236 of 5 stars$1.06-0.9%$5.50+418.9%-29.9%$55.07MN/A-0.9050News CoveragePositive NewsSNTISenti Biosciences2.7345 of 5 stars$2.11-2.3%$8.50+302.8%-43.3%$55.03M$2.56M-0.194CRVOCervoMed3.2901 of 5 stars$6.28+3.8%$27.63+339.9%-64.9%$54.64M$9.74M-2.884News CoveragePositive NewsCNTBConnect Biopharma3.3266 of 5 stars$0.98-2.0%$7.00+614.3%-21.7%$54.45M$26.03M0.00110News CoverageHigh Trading VolumeANLAdlai Nortye1.4427 of 5 stars$1.47-5.2%$9.00+512.2%-53.8%$54.24M$5M0.00127AVTXAvalo Therapeutics3.0535 of 5 stars$4.99+4.4%$30.00+501.2%-59.7%$54.04M$440K0.0040News CoverageGANXGain Therapeutics3.0987 of 5 stars$1.80-8.6%$8.20+355.6%+36.8%$53.91M$50K-2.0920Analyst ForecastGap DownKRONKronos Bio3.0839 of 5 stars$0.88+1.5%$1.63+84.7%-24.8%$53.72M$9.85M-0.82100OTLKOncobiologics1.6707 of 5 stars$1.60flat$9.60+500.0%-75.9%$53.71MN/A-1.7620INMBINmune Bio1.6358 of 5 stars$2.31-56.7%$22.80+887.0%-70.8%$53.08M$10K-1.2010Trending NewsAnalyst DowngradeGap DownHigh Trading Volume Related Companies and Tools Related Companies PMVP Competitors SNTI Competitors CRVO Competitors CNTB Competitors ANL Competitors AVTX Competitors GANX Competitors KRON Competitors OTLK Competitors INMB Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GOVX) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe $100 Trillion AI Story No One Is Telling YouJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GeoVax Labs Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GeoVax Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
